Abstract: The present invention is a smart equipment with bidirectional diagnosis and therapy device, comprising a power supply unit, an input unit, a microprocessor, a digital signal converter, a signal transmission unit, a high-voltage diagnosis and therapy unit and a smart equipment. Generally, the power supply unit is used for providing required power, while the digital signal converter is used for connecting the signal transmission unit and the smart equipment, such that a diagnosis and therapy signal sent back from the high-voltage diagnosis and therapy unit is acquired by the smart equipment. The smart equipment is loaded with application software for processing the diagnosis and therapy signal correspondingly, and then enable the user to manipulate the high-voltage diagnosis and therapy unit for diagnosis and therapy via the input unit according to suggestion from application software. Thus, correct diagnosis and therapy is allowed for the user to achieve the best effect.

Abstract: Disclosed is a multi-functional electro-spoon needle therapeutic apparatus, which includes a top cover, locating pieces, a fixed lid, a rear cover, electro-spoon needles and an adjustment mechanism, wherein the locating pieces are respectively mounted on the top cover and the rear cover, and each locating piece is provided with a long groove; the fixed lid is respectively fixed on the top cover and the rear cover so as to respectively hold the locating pieces between the top cover and the fixed lid and between the rear cover and the fixed lid; the rear cover is arranged behind the top cover and connected to the top cover via the adjustment mechanism; and the electro-spoon needles are mounted in the long grooves of the locating pieces and can move along the long grooves. The apparatus has a simple structure, so a patient can perform acupuncture by himself.

Abstract: The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies.

Abstract: A cap for a container includes a base portion having a curved outer surface and being connectable to a container, the base having an indented portion on at least a part of said curved outer surface. An electronic display fits in the indented portion of the base portion and electronically connected to circuitry within the cap. A clear portion covers the electronic display. A multi-color light-emitting diode (LED) electronically connected to the circuitry within the cap.

Abstract: A feeding assembly includes a container having an open top and defining a liquid chamber therein for holding a liquid. A collar assembly defines a closure for the open top of the container upon assembly with the container. A vent assembly is positionable at least in part on the open top of the container and is configured to facilitate venting of the container to atmosphere as liquid exits the feeding assembly during feeding. The vent assembly being disposed intermediate the container and the nipple, has at least one opening through which liquid is able to flow from the container to the nipple during feeding. The vent assembly has a siphon member extending longitudinally of the feeding assembly and generally away from the nipple and is configured to facilitate the flow of liquid from the nipple back into the container when feeding is ceased and the container is oriented generally upright.

Abstract: A systems and methods for determining a position of a medical tube within a patient is provided. In one example, systems and methods are provided for a self- detection positioning system that is capable of determining a location of a distal end of a medical tube placed within a patient, and notifying a physician of the location of the distal end of the medical tube.

Abstract: Toothpaste compositions are disclosed. The toothpaste composition comprises a binder; a surface active agent; an abrasive; a humectant; and water; in which: (1) the abrasive is silica, the composition additionally comprises a silica thickener, and the composition comprises 1 to 7 wt % of the silica thickener, less than 15 wt % of the silica abrasive, 45 to 70 wt % water, 0.8 to 3.0 wt % of a surface active agent; 0.05 to 3.0 wt % the binder; or (2) the abrasive is silica, the composition additionally comprises a silica thickener, the composition comprises 2 to 22 wt % total silica, 0.8 to 3.0 wt % of a surface active agent; 0.05 to 3.0 wt % the binder, and the composition additionally comprises about 0.1 to 8.0 wt % of non-colloidal microcrystalline cellulose, colloidal microcrystalline cellulose, or a mixture thereof; or (3) the binder is a calcium based abrasive, the binder is a cellulose gum, and the composition comprises 25 to 55 wt % of the calcium based abrasive, 35 to 60 wt % water, 0.8 to 3.

Abstract: A phosphonate salt for use in a dental treatment, in particular in a root canal treatment, for the manufacture of a pharmaceutical preparation, in particular as decalcifying agent and a pharmaceutical preparation for use in the dental treatment comprising a phosphonate salt and/or a phosphonate salt and a hydroxide compound in solid form are provided. A method of producing a pharmaceutical preparation and a kit of parts (1, 1?) for manufacturing a pharmaceutical preparation for use in the dental treatment are provided.

Abstract: The invention relates to dental materials which contain at least one compound of Formula I The materials are characterized by very good mechanical properties after curing.

Abstract: The present invention relates to composite powder having enhanced water repellency and oil absorbency by means of even impregnation of inorganic powder particles with a super-water-repellent porous polymer. The composite powder prepared by means of a one-step spraying procedure of electro-spraying or spray drying, according to the present invention, shows super water repellency and maximized oil absorbency by means of increased porosity of porous polymethyl methacrylate (PMMA) and even impregnation with titanium dioxide (TiO2) nanoparticles.

Abstract: A method of making a stable detersive surfactant containing personal care composition comprising the steps of emulsifying a stabilizing agent in the presence of anionic surfactant to form an emulsion containing droplets having a particle size of from about 0.1 to about 10 um. These particles are then cooled to form a stabilizing premix at a rate of about 10 to about 1000 C/min to form crystals from the droplets, the crystals having a maximum dimension of about 0.1 to about 3 um. These crystals are then added to a detersive surfactant containing personal care composition to increase stability.

Abstract: A microcapsule composition is provided, which contains a polyurea or polyurethane microcapsule, an alkylnaphthalenesulfonate formaldehyde condensate, and polyvinylpyrrolidone. Also disclosed is a process of preparing the microcapsule composition and a consumer product having such a microcapsule composition.

Abstract: A microcapsule composition comprising at least one polymer substantially disposed as a semi-permeable shell around a buffered solution and at least one therapeutic agent, wherein the therapeutic agent permeates the shell, and wherein the composition is suitable for delivery to a mammal. This invention also provides related compositions, products and methods.

Abstract: Disclosed is method of protecting skin from ultraviolet radiation which comprises the step of administering a skin protective composition. The skin protective composition disclosed in the present invention includes a compound, which not only can protect normal human skin against UV-induced damage, but also exhibits protective benefits on the skin of patients with G6PD-deficiency.

Abstract: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a bodywash, shampoo, conditioner, lotion, gel, soap, cream, hand sanitizer, spray or mousse and can be used by an individual during their normal hygiene processes, such as during a shower or bath or while applying a body product to their skin or hair.

Abstract: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a bodywash, shampoo, conditioner, lotion, gel, soap, cream, hand sanitizer, spray or mousse and can be used by an individual during their normal hygiene processes, such as during a shower or bath or while applying a body product to their skin or hair.

Abstract: The disclosure relates to systems and compositions comprising the systems for use in chemical treatment of keratinous substrates, such as the hair. The systems and compositions comprising the systems comprise at least one active agent and at least one acid. Methods of treating keratinous substrates with the systems and compositions comprising the systems are also disclosed.

Abstract: The present invention relates to a process for treating keratin fibres, in particular the hair, comprising: a) the application, to said fibres, of a composition having a pH greater than or equal to 8, at 25° C., and comprising at least one amino acid chosen from those of formulae (I) and (II) below, and also the betaine forms thereof, the optical isomers thereof, the solvates thereof such as the hydrates, and the organic or inorganic base or acid salts thereof: in which formulae (I) and (II): —R represents a hydrogen atom, or a linear or branched, preferably linear, C1-C5 alkyl group, said alkyl group being optionally substituted with at least one group chosen from hydroxyl, —C(O)—OH, —S(O)2—OH, —C(O)—O?, M+, and —S(O)2-O?, M+, with M+ representing a cationic counterion such as an alkali metal, alkaline-earth metal, or ammonium,20 —n is 0 or 1; b) followed by a step of straightening/relaxing the keratin fibres by means of a straightening iron at a temperature of at least 100° C.

Abstract: The present invention relates to a soothing composition, comprising (a) menthol compounds, and (b) one or more cosmetically acceptable carriers.

Abstract: A cleaning cream containing PVA particles has PVA particles being uniformly dispersed in a cleaning cream. Moisture content of the cleaning cream is at the range of 0.1˜23%. The cleaning cream comprises a least a surfactant. The PVA particles has glycerol and PVA in which molecular weight of the PVA is 110,000˜120,000. The PVA particles remain as particle form in the cleaning cream.

Abstract: The disclosure relates to a cosmetic composition for the temporary shaping of hair, containing a combination of two specific anionic copolymers. The cosmetic composition provides an extremely good moisture resistance.

Abstract: The present disclosure relates to cosmetic compositions for personal care. In one example, a cosmetic preparation includes, based on the total weight of the composition, an oil mixture in a total quantity of about 40 to about 99 wt. %. The oil mixture includes a) at least one ester, which is formed from at least one linear or branched, saturated or unsaturated mono-, di-, or tricarboxylic acid with 3 to 30 carbon atoms, wherein the acid can optionally contain one or more hydroxyl groups, and at least one linear or branched, saturated or unsaturated alcohol with 1 to 30 carbon atoms, b) at least cyclic polydimethylsiloxane, and c) at least one linear polydimethylsiloxane which has a kinematic viscosity of less than about 20 cSt at 25° C.

Abstract: Disclosed is a hydrophilic silicone composition comprising an oral care substance. The composition is based on polysiloxanes having a high water-uptake capability. An aqueous solution or dispersion of the oral care substance can be soaked into the polysiloxane, whereby the resulting composition shows favorable release characteristics. The use of hydrophilically modified polysiloxanes, possibly in conjunction with unmodified hydrophobic polysiloxanes, allows for the convenient production of desired shapes, advantageously based on a dental imprint. The hydrophilic modification of the polysiloxane is particularly by including a hydrophilic vinyl monomer, particularly an alpha-olefinic soap, into the composition prior to curing.

Abstract: A solid cosmetic composition includes a vegetable butter. The solid composition has dispersed therein gas bubbles, and the gas bubbles form at least 20% of the volume of the solid cosmetic composition.

Abstract: A kit for preparing a customized cosmetic includes at least one of five cosmetic bases. Each of the five cosmetic bases correspond to at least one of a plurality of primary categories. The kit additionally includes at least one cosmetic active ingredient for admixing with the at least one cosmetic base. The at least one cosmetic active ingredient corresponds to at least one of the plurality of primary categories or at least one of the plurality of secondary categories.

Abstract: An omega-7 fatty acid composition from a raw material Tribonema sp. obtained under heterotrophy and/or mixotrophy and a method of cultivation of Tribonema sp. by way of heterotrophy and/or mixotrophy. The content of omega-7 fatty acid in the omega-7 fatty acid composition is 30% to 70%. The method of cultivation involves nutrient composition of a culture medium, cultivation conditions, and operation steps of a cultivation process. An application of the method in the production of Tribonema biomass, lipid rich in omega-7 fatty acid, products with the biomass and/or the lipid as the raw material, etc.

Abstract: A ferment extract from a bacterial strain the Eupenicillium crustaceum species useful in the cosmetic treatment and/or care of the skin, mucous membranes, hair and/or nails and cosmetic uses of same.

Abstract: We disclose a composition comprising an echogenic liposome (ELIP) having an exterior surface, an interior surface, and at least one bilayer comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, and a thrombolytic compound trapped by the ELIP. We also disclose a method of treating a medical condition in a patient characterized by a thrombus in the patient's vasculature, comprising administering to the patient the composition in an amount effective to reduce the size of the thrombus.

Abstract: The invention relates to pharmaceutical formulations for use in the administration of lipophilic medicaments via mucosal surfaces. In particular the invention provides pharmaceutical formulations for use in administration of a lipophilic medicament via a mucosal surface which upon hydration form an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament. The invention further provides pharmaceutical formulations which contain, as active ingredients, specific combinations of cannabinoids in pre-defined ratios.

Abstract: Described herein, inter alia, are compositions of cell penetrating high density brush peptide polymer, drug delivery vehicles for delivering cell penetrating peptides and drugs. Also provided is a methodology for protecting active peptides from proteolysis by packaging them into high-density brush polymers via ring opening metathesis polymerization (ROMP), using an easily-prepared catalyst initiator. The graft-through polymerization of norbomyl-peptide monomers via ROMP can result in structures that resist proteolysis relative to their monomeric analogues in a manner dependent on their degree of polymerization (REFS). Polymerized peptides, while protected from proteolysis, maintain their intended biological function and are capable of any of the functions inherent to the peptide, such as binding a receptor or ligand, initiating a signaling pathway, penetrating a cell, or inducing a therapeutic effect.

Abstract: The present technology provide compositions that are drug delivery systems for the sustained release of anti-stenotic drugs for the treatment and prevention of occlusion of blood vessels, particularly after perivascular surgery. The compositions include a hydrogel, unimolecular micelles dispersed within the hydrogel, and an effective amount of anti-stenotic drug dispersed within the unimolecular micelle. The hydrogel may be a di-or tri-block copolymer comprising one block of poly(ethylene glycol) (PEG) and one or two blocks of poly(lactic-co-glycolic acid) (PLGA). The unimolecular micelle may include three domains: a dendritic polymer core, hydrophobic block polymers (e.g., PVL, PVCL, and/or PCL) attached to the core and PEG attached to the hydrophobic block polymers.

Abstract: The present invention discloses a cannabis based emulsion formulation for use in various medical conditions and optionally with various pharmaceutical or nutraceutical compositions, wherein the oily fraction used contains about 50% cannabinoids. The present invention further discloses methods of manufacturing and uses of the aforementioned composition.

Abstract: Disclosed is a stable micro-emulsion comprising: water; a water soluble, hydroxy-containing polymeric material; (c) at least one a hydrotrop; and (d) a propellant comprising trans-1,3,3,3-tetrafluoropropene

Abstract: The present disclosure relates to methods of treatment for various diseases, including chronic obstructive pulmonary disease, involving administration of compositions comprising membrane-enclosed vesicles. The membrane-enclosed vesicles may be derived from a stem cell such as a mesenchymal stem cell.

Abstract: Immunoregulatory spherical nucleic acids (irSNAs) composed of a lipid containing core and an inert Nucleic non-TLR antagonistic oligonucleotide shell are provided. Acid Shell These it-SNAs are useful for modulating an immune response.

Abstract: A cochleate composition is disclosed. Following oral administration of the cochleate composition, the pharmacologically active agent is found at higher concentrations in the tissue relative to plasma. Oral administration of these cochleate compositions also preferentially targets infected or inflamed tissue as compared to tissue in a healthy subject. The cochleate composition contains a size-regulating agent that reduces cochleate particle size, such as a lipid-anchored polynucleotide, a lipid-anchored sugar, a lipid-anchored polypeptide, or a bile salt (such as oxycholate or deoxycholate). Also disclosed are methods of treatment using the cochleate composition and methods of increasing the concentration of a pharmacologically active agent in an infected tissue relative to the concentration of the pharmacologically active agent in the plasma or the tissue of a healthy subject.

Abstract: The present invention relates to a lyophilized composition comprising killed cancer cells with substantially retained immunogenicity and morphology, an intracellular cryopreservative such as trehalose and an extracellular cryopreservative such as polyvinylpyrrolidone. The present invention also relates to a process for the preparation of said lyophilized composition. The lyophilized composition of the present invention can be used for cancer immunotherapy.

Abstract: A solid dispersion comprising: (a) a pharmaceutical active ingredient or a nutraceutical active ingredient having a low solubility; and (b) sodium or potassium alginate. In addition, a drug dosage form prepared from such a solid dispersion.

Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.

Abstract: The invention relates to pharmaceutical formulation in form of a film-coating tablet comprising sembragiline or a salt thereof.

Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.

Abstract: The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form.

Abstract: The present invention relates to a natural lubricant for direct compression and a method of preparing a synthetic additive-free natural tablet using the same. More particularly, the invention provides a crude fat-containing bean powder, which is used as a natural lubricant, and a method of preparing a natural tablet using the bean powder by a dry granulation process which is carried out using a roller compactor.

Abstract: Bioavailable liquid softgel fill compositions comprising a) fexofenadine or a fexofenadine salt; b) a matrix comprising a pharmaceutically acceptable poly(alkylene glycol), optionally a pharmaceutically acceptable alkylene glycol, optionally a pharmaceutically acceptable polymeric solubilizing agent, and optionally a pharmaceutically acceptable surfactant; and c) a pharmaceutically acceptable acidulant are disclosed. Also disclosed are methods for the preparation of such fill compositions, and softgel capsules containing the bioavailable liquid fill composition.

Abstract: A non-bleeding curcumin (NBC) which eliminate the problems of color bleeding, color leaching, color staining and dusting during the industrial processing of curcumin and its methods of preparation is disclosed in the invention. The invention also provides a water based process of preparation of food grade non-bleeding curcumin which is free of synthetic excipients.

Abstract: Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.

Abstract: The object of the present invention is the method for obtaining a pharmaceutical composition of polymeric nanoparticles for the treatment of neuropathic pain caused by peripheral nerve compression, related to the pharmaceutical industry and nanotechnology. The invention particularly relates to a novel system for orally administering the cannabinoid drug CB13 based on polymeric nanoparticles capable of alleviating pain for nine days following a single oral administration of an aqueous suspension of nanoparticles.

Abstract: The invention is concerned with a transdermal therapeutic system (TTS) comprising buprenorphine and a method of manufacturing such a TTS. The transdermal therapeutic system is used for the transdermal administration of buprenorphine and analogues thereof. In particular, the invention relates to the use of a transdermal therapeutic system (TTS) for analgesic purposes. The TTS according to the invention comprises a transdermal drug delivery composition comprising buprenorphine and an adhesive component, which is a mixture of a crosslinked and a non-crosslinked acrylic polymer and a penetration enhancer comprising a keto acid.

Abstract: Compositions and methods for maintaining healthy skin and alleviating skin conditions such as redness, inflammation, irritation and skin aging, as well as for maintaining healthy scalp and hair are disclosed. The oral compositions disclosed comprise antioxidants including lycopene, gallic acid and ascorbic acid. Preferably lycopene has been water-extracted, more preferably under acid conditions. In the method of treatment aspect of the invention, an oral composition containing antioxidant(s) is administered to a person concurrently with a topical treatment for said skin conditions. Preferred topical compositions comprise cyclohexane polyols, such as cyclohexanediol or cyclohexanetriol.

Abstract: Systems and methods provide sugar alcohol to heat stressed ruminants to improve performance. During periods of high temperature or humidity, heat stressed ruminants may exhibit decreased dry matter intake, and in response, an effective amount of sugar alcohol such as sorbitol may be provided in the ruminant diet to cause performance to increase, which may include increased milk yield, improved feed efficiency or both compared to heat stressed dairy cattle without sugar alcohol in the diet.